{"entity":{"id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","aka":["EVOLVE-BDT"],"tldr":"A phase 2 trial of abemaciclib, everolimus and capecitabine in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.","summary":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies is a phase 2, interventional study registered as NCT07340541 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 700 participants, started 2026-02-16 and due to reach its primary completion in 2031-06-02. Interventions recorded: SERD* + abemaciclib; SERD* + everolimus; SERD* + everolimus or capecitabine; SOC; Antiandrogen. Conditions listed: Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; Estrogen-receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07340541","url":"https://clinicaltrials.gov/study/NCT07340541"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["abemaciclib","everolimus","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07340541","phase":"2","setting":"TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT)","sponsor":"UNC Lineberger Comprehensive Cancer Center","enrolled":700,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07340541/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}